Prilinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Prilinostat mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Prilinostat mesylate overview

Prilinostat mesylate is under development for the treatment of relapsed or refractory hematological tumors including B-cell lymphoma, diffuse large B cell lymphoma, multiple myeloma, B cell acute leukemia, T-cell lymphoma, T-cell acute leukemia after standard regimen therapy. The drug candidate is administered through intravenous route and acts by targeting histone deacetylase (HDAC).

For a complete picture of Prilinostat mesylate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.